391 related articles for article (PubMed ID: 26281838)
21. Peripheral T-cell lymphoma--not otherwise specified.
Savage KJ; Ferreri AJ; Zinzani PL; Pileri SA
Crit Rev Oncol Hematol; 2011 Sep; 79(3):321-9. PubMed ID: 20702104
[TBL] [Abstract][Full Text] [Related]
22. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas.
Zinzani PL; Bonthapally V; Huebner D; Lutes R; Chi A; Pileri S
Crit Rev Oncol Hematol; 2016 Mar; 99():214-27. PubMed ID: 26811013
[TBL] [Abstract][Full Text] [Related]
23. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma.
Kewalramani T; Zelenetz AD; Teruya-Feldstein J; Hamlin P; Yahalom J; Horwitz S; Nimer SD; Moskowitz CH
Br J Haematol; 2006 Jul; 134(2):202-7. PubMed ID: 16759221
[TBL] [Abstract][Full Text] [Related]
24. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors.
Mak V; Hamm J; Chhanabhai M; Shenkier T; Klasa R; Sehn LH; Villa D; Gascoyne RD; Connors JM; Savage KJ
J Clin Oncol; 2013 Jun; 31(16):1970-6. PubMed ID: 23610113
[TBL] [Abstract][Full Text] [Related]
25. Risk factors and timing of autologous stem cell transplantation for patients with peripheral T-cell lymphoma.
Yamasaki S; Chihara D; Kim SW; Kawata T; Mizuta S; Ago H; Chou T; Yamane T; Uchiyama H; Oyake T; Miura K; Saito B; Taji H; Nakamae H; Miyamoto T; Fukuda T; Kanda J; Atsuta Y; Suzuki R
Int J Hematol; 2019 Feb; 109(2):175-186. PubMed ID: 30430419
[TBL] [Abstract][Full Text] [Related]
26. Current Treatment of Peripheral T-cell Lymphoma.
Stuver R; Epstein-Peterson ZD; Johnson WT; Khan N; Lewis N; Moskowitz AJ; Sauter CS; Horwitz S
Oncology (Williston Park); 2022 May; 36(5):293-305. PubMed ID: 35576176
[TBL] [Abstract][Full Text] [Related]
27. Hematopoietic stem cell transplantation in the treatment of peripheral T-cell lymphomas.
Majhail NS; Burns LJ
Curr Hematol Rep; 2005 Jul; 4(4):252-9. PubMed ID: 16009039
[TBL] [Abstract][Full Text] [Related]
28. Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation.
Kahl C; Leithäuser M; Wolff D; Steiner B; Hartung G; Casper J; Freund M
Ann Hematol; 2002 Nov; 81(11):646-50. PubMed ID: 12454703
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.
Coiffier B; Federico M; Caballero D; Dearden C; Morschhauser F; Jäger U; Trümper L; Zucca E; Gomes da Silva M; Pettengell R; Weidmann E; d'Amore F; Tilly H; Zinzani PL
Cancer Treat Rev; 2014 Oct; 40(9):1080-8. PubMed ID: 25199959
[TBL] [Abstract][Full Text] [Related]
30. The aggressive peripheral T-cell lymphomas: 2015.
Armitage JO
Am J Hematol; 2015 Jul; 90(7):665-73. PubMed ID: 26031230
[TBL] [Abstract][Full Text] [Related]
31. The role of high-dose therapy in peripheral T-cell lymphomas.
Reimer P; Rüdiger T; Wilhelm M
Clin Lymphoma Myeloma; 2006 Mar; 6(5):373-9. PubMed ID: 16640812
[TBL] [Abstract][Full Text] [Related]
32. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
33. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect.
Dodero A; Spina F; Narni F; Patriarca F; Cavattoni I; Benedetti F; Ciceri F; Baronciani D; Scimè R; Pogliani E; Rambaldi A; Bonifazi F; Dalto S; Bruno B; Corradini P
Leukemia; 2012 Mar; 26(3):520-6. PubMed ID: 21904377
[TBL] [Abstract][Full Text] [Related]
34. Controversies in lymphoma: the role of hematopoietic cell transplantation for mantle cell lymphoma and peripheral T cell lymphoma.
Dreger P; Laport GG
Biol Blood Marrow Transplant; 2008 Jan; 14(1 Suppl 1):100-7. PubMed ID: 18162229
[TBL] [Abstract][Full Text] [Related]
35. Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin.
Nizamuddin I; Galvez C; Pro B
Semin Hematol; 2021 Apr; 58(2):85-94. PubMed ID: 33906726
[TBL] [Abstract][Full Text] [Related]
36. Bone Marrow Transplantation for Peripheral T-Cell Non-Hodgkins' Lymphoma in First Remission.
Sharma M; Pro B
Curr Treat Options Oncol; 2015 Jul; 16(7):34. PubMed ID: 26076798
[TBL] [Abstract][Full Text] [Related]
37. Peripheral T-cell lymphoma: a case-based discussion of recent advances in patient management.
Franco CM; Popplewell LL; Horwitz SM
Clin Adv Hematol Oncol; 2011 Apr; 9(4 Suppl 9):1-16. PubMed ID: 21559001
[TBL] [Abstract][Full Text] [Related]
38. The clinical features, treatment, and prognostic factors for peripheral T-cell lymphomas: A single-institution analysis of 240 Chinese patients.
Chen H; Tao Y; Zhou Y; Liu P; Yang J; He X; Zhou S; Qin Y; Song Y; Gui L; Zhang C; Yang S; Shi Y
Asia Pac J Clin Oncol; 2023 Oct; 19(5):e202-e214. PubMed ID: 35821612
[TBL] [Abstract][Full Text] [Related]
39. Hematopoietic SCT for peripheral T-cell lymphoma.
Gutiérrez A; Caballero MD; Pérez-Manga G; Rodriguez J
Bone Marrow Transplant; 2008 Dec; 42(12):773-81. PubMed ID: 18936735
[TBL] [Abstract][Full Text] [Related]
40. Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management.
Shustov A; Soma L
Cancer Treat Res; 2019; 176():127-144. PubMed ID: 30596216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
